Literature DB >> 24378418

Associations between serum cholesterol levels and cerebral amyloidosis.

Bruce Reed1, Sylvia Villeneuve2, Wendy Mack3, Charles DeCarli1, Helena C Chui3, William Jagust2.   

Abstract

IMPORTANCE: Because deposition of cerebral β-amyloid (Aβ) seems to be a key initiating event in Alzheimer disease (AD), factors associated with increased deposition are of great interest. Whether elevated serum cholesterol levels act as such a factor is unknown.
OBJECTIVE: To investigate the association between serum cholesterol levels and cerebral Aβ during life early in the AD process. DESIGN, SETTING, AND PARTICIPANTS: A multisite, university medical center-based, cross-sectional analysis of potential associations between contemporaneously assayed total serum cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and cerebral Aβ, measured with carbon C11-labeled Pittsburgh Compound B (PIB) positron emission tomography. Seventy-four persons (mean age, 78 years) were recruited via direct outreach in stroke clinics and community senior facilities following a protocol designed to obtain a cohort enriched for cerebrovascular disease and elevated vascular risk. Three patients had mild dementia. All others were clinically normal (n = 33) or had mild cognitive impairment (n = 38).
RESULTS: Cerebral Aβ was quantified using a Global PIB Index, which averages PIB retention in cortical areas prone to amyloidosis. Statistical models that controlled for age and the apolipoprotein E ε4 allele revealed independent associations among the levels of LDL-C, HDL-C, and PIB index. Higher LDL-C and lower HDL-C levels were both associated with a higher PIB index. No association was found between the total cholesterol level and PIB index. No association was found between statin use and PIB index, and controlling for cholesterol treatment in the statistical models did not alter the basic findings. CONCLUSIONS AND RELEVANCE: Elevated cerebral Aβ level was associated with cholesterol fractions in a pattern analogous to that found in coronary artery disease. This finding, in living humans, is consistent with prior autopsy reports, epidemiologic findings, and animal and in vitro work, suggesting an important role for cholesterol in Aβ processing. Because cholesterol levels are modifiable, understanding their link to Aβ deposition could potentially and eventually have an effect on retarding the pathologic cascade of AD. These findings suggest that understanding the mechanisms through which serum lipids modulate Aβ could offer new approaches to slowing Aβ deposition and thus to reducing the incidence of AD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24378418      PMCID: PMC4083819          DOI: 10.1001/jamaneurol.2013.5390

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  42 in total

Review 1.  Linking lipids to Alzheimer's disease: cholesterol and beyond.

Authors:  Gilbert Di Paolo; Tae-Wan Kim
Journal:  Nat Rev Neurosci       Date:  2011-03-30       Impact factor: 34.870

2.  Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.

Authors:  D L Sparks; Y M Kuo; A Roher; T Martin; R J Lukas
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

3.  Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

Authors:  L M Refolo; B Malester; J LaFrancois; T Bryant-Thomas; R Wang; G S Tint; K Sambamurti; K Duff; M A Pappolla
Journal:  Neurobiol Dis       Date:  2000-08       Impact factor: 5.996

4.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

5.  High total cholesterol levels in late life associated with a reduced risk of dementia.

Authors:  M M Mielke; P P Zandi; M Sjögren; D Gustafson; S Ostling; B Steen; I Skoog
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

6.  Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain.

Authors:  Maura Heverin; Steve Meaney; Dieter Lütjohann; Ulf Diczfalusy; John Wahren; Ingemar Björkhem
Journal:  J Lipid Res       Date:  2005-03-01       Impact factor: 5.922

7.  Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study.

Authors:  Zaldy Sy Tan; Sudha Seshadri; Alexa Beiser; Peter W F Wilson; Douglas P Kiel; Michael Tocco; Ralph B D'Agostino; Philip A Wolf
Journal:  Arch Intern Med       Date:  2003-05-12

8.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

9.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study.

Authors:  Stella Trompet; Peter van Vliet; Anton J M de Craen; Jelle Jolles; Brendan M Buckley; Michael B Murphy; Ian Ford; Peter W Macfarlane; Naveed Sattar; Chris J Packard; David J Stott; Jim Shepherd; Eduard L E M Bollen; Gerard J Blauw; J Wouter Jukema; Rudi G J Westendorp
Journal:  J Neurol       Date:  2009-08-04       Impact factor: 4.849

10.  Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts.

Authors:  Robert Ehehalt; Patrick Keller; Christian Haass; Christoph Thiele; Kai Simons
Journal:  J Cell Biol       Date:  2003-01-06       Impact factor: 10.539

View more
  83 in total

1.  Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.

Authors:  Sylvia Villeneuve; William J Jagust
Journal:  J Prev Alzheimers Dis       Date:  2015-03

2.  Vascular Burden Score Impacts Cognition Independent of Amyloid PET and MRI Measures of Alzheimer's Disease and Vascular Brain Injury.

Authors:  Charles DeCarli; Sylvia Villeneuve; Pauline Maillard; Danielle Harvey; Baljeet Singh; Owen Carmichael; Evan Fletcher; John Olichney; Sarah Farias; William Jagust; Bruce Reed; Dan Mungas
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

3.  Amyloid beta accumulation in HIV-1 infected brain: the role of altered cholesterol homeostasis.

Authors:  Xuesong Chen; Liang Hui; Jonathan D Geiger
Journal:  Clin Res HIV AIDS       Date:  2014-08-31

Review 4.  ATP-binding cassette transporter A1: from metabolism to neurodegeneration.

Authors:  Radosveta Koldamova; Nicholas F Fitz; Iliya Lefterov
Journal:  Neurobiol Dis       Date:  2014-05-17       Impact factor: 5.996

5.  Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum.

Authors:  Natacha Lorius; Joseph J Locascio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Anand Viswanathan; Gad A Marshall
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

Review 6.  Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Exp Gerontol       Date:  2014-09-28       Impact factor: 4.032

Review 7.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

8.  Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults.

Authors:  Vijay K Ramanan; Scott A Przybelski; Jonathan Graff-Radford; Anna M Castillo; Val J Lowe; Michelle M Mielke; Rosebud O Roberts; Robert I Reid; David S Knopman; Clifford R Jack; Ronald C Petersen; Prashanthi Vemuri
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.

Authors:  Julie M Zissimopoulos; Douglas Barthold; Roberta Diaz Brinton; Geoffrey Joyce
Journal:  JAMA Neurol       Date:  2017-02-01       Impact factor: 18.302

10.  Impact of lifestyle dimensions on brain pathology and cognition.

Authors:  Stefanie Schreiber; Jacob Vogel; Henry D Schwimmer; Shawn M Marks; Frank Schreiber; William Jagust
Journal:  Neurobiol Aging       Date:  2016-01-30       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.